Literature DB >> 17494078

Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections.

Rebecca Pellett Madan1, Pedro M M Mesquita, Natalia Cheshenko, Bingwen Jing, Vikas Shende, Esmeralda Guzman, Taylor Heald, Marla J Keller, Steven L Regen, Robin J Shattock, Betsy C Herold.   

Abstract

Molecular umbrella compounds may function as novel topical microbicides to prevent human immunodeficiency virus (HIV) and herpes simplex virus (HSV) infections. In a preliminary structure-activity investigation, one umbrella compound, designated Spm8CHAS, was identified which inhibited both HIV and HSV infections with no cellular toxicity. The objectives of the current studies were to define its spectrum of antiviral activity, characterize its mechanism of action, and explore the possibility of combining Spm8CHAS with HIV-specific reverse transcriptase inhibitors. Spm8CHAS inhibited infections by laboratory and clinical R5 and X4 clade B and clade C HIV strains in cell culture. Ectocervical tissue explants exposed to HIV-1(BaL) in the presence of Spm8CHAS were completely protected (50% inhibitory concentration [IC(50)], 13.6 microg/ml), and transfer of virus to target T cells via migratory cells was abolished (IC(50), 3.8 microg/ml). Spm8CHAS inhibited HSV-2 infection of epithelial cells 10,000-fold if present throughout the infection. Notably, adding Spm8CHAS to cultures following HSV entry significantly reduced viral infection, indicating that the drug also acts postentry. Subsequent studies indicated that Spm8CHAS blocks cell-to-cell spread of HSV. Confocal microscopy using a fluorescently labeled analog of Spm8CHAS demonstrated that this conjugate crosses the plasma cell membrane and is transported to the nucleus. Combinations of Spm8CHAS with UC-781 or 9-[R-2-(phosphonylmethoxy)propyl] adenine monohydrate in vitro exhibited additive anti-HIV activity with preserved anti-HSV activity. The abilities of Spm8CHAS to inhibit primary isolates of HIV, block HSV infection postentry, and cross cell membranes support the development of a combination microbicide containing Spm8CHAS with an HIV-specific reverse transcriptase inhibitor to prevent both HIV and HSV infections by multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17494078      PMCID: PMC1933367          DOI: 10.1128/JVI.02851-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

Authors:  Marla J Keller; Bouchra Zerhouni-Layachi; Natalia Cheshenko; Minnie John; Kathleen Hogarty; Andrea Kasowitz; Cindy L Goldberg; Sylvan Wallenstein; Albert T Profy; Mary E Klotman; Betsy C Herold
Journal:  J Infect Dis       Date:  2005-11-17       Impact factor: 5.226

2.  Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.

Authors:  P Greenhead; P Hayes; P S Watts; K G Laing; G E Griffin; R J Shattock
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection.

Authors:  Ehsan Hazrati; Benjamin Galen; Wuyuan Lu; Wei Wang; Yan Ouyang; Marla J Keller; Robert I Lehrer; Betsy C Herold
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

4.  Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study.

Authors:  Charles J N Lacey; Anne Wright; Jonathan N Weber; Albert T Profy
Journal:  AIDS       Date:  2006-04-24       Impact factor: 4.177

5.  Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates.

Authors:  Hong Lu; Qian Zhao; Greg Wallace; Shuwen Liu; Yuxian He; Robin Shattock; A Robert Neurath; B Shibo Jiang
Journal:  AIDS Res Hum Retroviruses       Date:  2006-05       Impact factor: 2.205

6.  Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells.

Authors:  Benjamin Galen; Natalia Cheshenko; Ana Tuyama; Bharat Ramratnam; Betsy C Herold
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

7.  In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.

Authors:  Mohammad M Hossain; Michael A Parniak
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 8.  Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?

Authors:  Leonid Margolis; Robin Shattock
Journal:  Nat Rev Microbiol       Date:  2006-04       Impact factor: 60.633

9.  Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Authors:  Kenneth H Mayer; Lisa A Maslankowski; Fang Gai; Wafaa M El-Sadr; Jessica Justman; Antonia Kwiecien; Benoît Mâsse; Susan H Eshleman; Craig Hendrix; Kathleen Morrow; James F Rooney; Lydia Soto-Torres
Journal:  AIDS       Date:  2006-02-28       Impact factor: 4.177

Review 10.  Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

Authors:  Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177

View more
  20 in total

1.  Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds.

Authors:  Chen-Jei Tai; Chia-Lin Li; Cheng-Jeng Tai; Chien-Kai Wang; Liang-Tzung Lin
Journal:  J Vis Exp       Date:  2015-10-29       Impact factor: 1.355

Review 2.  Bioconjugate-based molecular umbrellas.

Authors:  Vaclav Janout; Steven L Regen
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

Review 3.  Novel targets for antiretroviral therapy: clinical progress to date.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Drugs       Date:  2009       Impact factor: 9.546

4.  Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.

Authors:  Pedro M M Mesquita; Rachna Rastogi; Theodore J Segarra; Ryan S Teller; N Merna Torres; Ashley M Huber; Patrick F Kiser; Betsy C Herold
Journal:  J Antimicrob Chemother       Date:  2012-03-30       Impact factor: 5.790

5.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

6.  Griffithsin protects mice from genital herpes by preventing cell-to-cell spread.

Authors:  Briana Nixon; Martha Stefanidou; Pedro M M Mesquita; Esra Fakioglu; Theodore Segarra; Lisa Rohan; William Halford; Kenneth E Palmer; Betsy C Herold
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

7.  Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide.

Authors:  Debora Pinna; Pasqua Oreste; Tiziana Coradin; Anna Kajaste-Rudnitski; Silvia Ghezzi; Giorgio Zoppetti; Antonella Rotola; Rafaela Argnani; Guido Poli; Roberto Manservigi; Elisa Vicenzi
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

8.  Cellular entry and nuclear targeting by a highly anionic molecular umbrella.

Authors:  Mohamed Mehiri; Bingwen Jing; Danielle Ringhoff; Vaclav Janout; Lynne Cassimeris; Steven L Regen
Journal:  Bioconjug Chem       Date:  2008-08-06       Impact factor: 4.774

9.  Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model.

Authors:  Pedro M M Mesquita; Sarah S Wilson; Philippe Manlow; Lucia Fischetti; Marla J Keller; Betsy C Herold; Robin J Shattock
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

Review 10.  Novel approaches in fighting herpes simplex virus infections.

Authors:  Sarah S Wilson; Esra Fakioglu; Betsy C Herold
Journal:  Expert Rev Anti Infect Ther       Date:  2009-06       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.